Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme

• Publication date

  2003-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/S-2003-43509PMID 14605997
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.

  2002cited by this paper
• Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development.

  2001cited by this paper
• Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.

  2001cited by this paper
• Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes.

  2001cited by this paper
• Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes.

  2001cited by this paper
• Type 2 diabetes: the epidemic of the new millennium.

  1999cited by this paper
• Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

  1999cited by this paper
• Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects.

  1998cited by this paper
• Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia

  1998cited by this paper
• Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections

  1998cited by this paper
• Glucagon-Like Peptide I Receptors in the Subfornical Organ and the Area Postrema Are Accessible to Circulating Glucagon-Like Peptide I

  1996cited by this paper
• Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM

  1996cited by this paper
• Glucagon-Like Peptide I Enhances the Insulinotropic Effect of Glibenclamide in NIDDM Patients and in the Perfused Rat Pancreas

  1996cited by this paper
• Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7–36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships

  1995cited by this paper
• Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

  1995cited by this paper
• Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.

  1994cited by this paper

• Randomised comparison of intravenous and subcutaneous routes of glucagon‐like peptide‐1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes

  2024cites this paper
• ON INCREASING THE AIFFINITY OF CRYSTALLINE MCROPARTICLE SURFACES FORACTIVE AGENTS

  2017cites this paper
• Dose response of continuous subcutaneous infusion of recombinant glucagon‐like peptide‐1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus

  2014cites this paper
• Dose response of subcutaneous GLP‐1 infusion in patients with type 2 diabetes

  2011cites this paper
• Roles of gastrointestinal and adipose tissue peptides in childhood obesity and changes after weight loss due to lifestyle intervention.

  2010cites this paper
• Fasting Glucagon-like Peptide-1 and Its Relation to Insulin in Obese Children Before and After Weight Loss

  2007cites this paper
• Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity, and stress.

  2005cites this paper
• Participation of Protein Kinases in the Stimulant Action of GLP-1 on 2-deoxy-D-glucose Uptake by Normal Rat Skeletal Muscle

  2005cites this paper
• GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats.

  2005cites this paper
• Gateways to clinical trials.

  2004cites this paper